12:00 AM
Sep 06, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Sativex sublingual cannabis extract spray regulatory update

Health Canada approved Sativex from GW Pharmaceuticals to treat spasticity due to multiple sclerosis (MS). The sublingual cannabis extract spray containing tetrahydrocannabinol (THC) and cannabidiol...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >